Cargando…
Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis
Background: The non-steroidal mineralocorticoid receptor antagonists (MRAs) are promising treatments in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). We conducted a meta-analysis to explore the efficacy and safety of the non-steroidal MRAs (finerenone, apararenone, esaxerenon...
Autores principales: | Jiang, Xinrui, Zhang, Zhengji, Li, Chunlu, Zhang, Shijin, Su, Qiang, Yang, Siyun, Liu, Xin, Hu, Ying, Pu, Xiaofeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243561/ https://www.ncbi.nlm.nih.gov/pubmed/35784710 http://dx.doi.org/10.3389/fphar.2022.896947 |
Ejemplares similares
-
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021) -
Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
por: Wu, Yichuan, et al.
Publicado: (2022) -
The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
por: Jaisser, Frédéric, et al.
Publicado: (2021) -
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020) -
PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
por: Orena, Stephen, et al.
Publicado: (2013)